Exo has launched SweepAI for cardiac and lung scanning on its Exo Iris ultrasound device.
With the launch of SweepAI and clearances from the U.S. Food and Drug Administration (FDA) in 2024, Exo Iris now includes automated AI-based indicators for congestive heart failure, detection of acute decompensated heart failure, stroke volume and heart rate, and determination of left ventricular wall hypertrophy, according to the company.
With enhancements such as automatic flow characterization, Iris is continually evolving, Exo said, adding it has also launched Exo U for ultrasound education.
